New insights into atherosclerotic plaque rupture

Postgraduate Medical Journal

Volumn 77, Issue 904, 2001, Pages 94-98

  Braganza, D M ^a   Bennett, M R ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MATRIX METALLOPROTEINASE;

APOPTOSIS; ARTERY RUPTURE; ARTICLE; ATHEROSCLEROTIC PLAQUE; DRUG MECHANISM; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; PATHOPHYSIOLOGY; SENESCENCE; VASCULAR SMOOTH MUSCLE;

CELL DEATH; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; CORONARY THROMBOSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCLE, SMOOTH, VASCULAR; MYOCARDIAL INFARCTION; RUPTURE, SPONTANEOUS;

EID: 0035140310     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pmj.77.904.94     Document Type: Article

References (67)

1. Coronary plaque disruption
2. Risk of thrombosis in human atherosclerotic plaques: Role of extracellular lipid, macrophage, and smooth muscle cell content
3. Role of smooth muscle cell death in advanced coronary primary lesions: Implications for plaque instability
4. Is vascular smooth muscle cell proliferation beneficial?
5. Molecular bases of the acute coronary syndromes
6. Plaque fissuring - The cause of acute myocardial infarction, sudden ischaemic death and crescendo angina
7. Cell proliferation in human coronary arteries
8. Proliferation in primary and restenotic coronary atherectomy tissue. Implications for antiproliferative therapy
9. Biphasic pattern of cell turnover characterizes the progression from fatty streaks to ruptured human atherosclerotic plaques
10. Adventitial myofibroblasts contribute to neointimal formation in injured poricine coronary arteries
11. Fibrous cap formation or destruction - The critical importance of vascular smooth muscle cell proliferation, migration and matrix formation
12. Localization of PDGF-B protein in macrophages in all phases of atherogenesis
13. Upregulation of IGF-I and collagen I mRNA in human atherosclerotic tissue is not accompanied by changes in type 1 IGF receptor or collagen III mRNA an in situ hybridization study
14. Human atherosclerosis. I. Cell constitution and characteristics of advanced lesions of the superficial femoral artery
15. Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques
16. Cellular composition of atherosclerotic and uninvolved human aortic subendothelial intima. Light-microscopic study of dissociated aortic cells
17. Primary cultures of human aortic intima cells as a model for testing antiatherosclerotic drugs. Effects of cyclic AMP, prostaglandins, calcium antagonists, antioxidants, and lipid-lowering agents
18. Clonal architecture of normal and atherosclerotic aorta - Implications for atherogenesis and vascular development
19. Evidence for apoptosis in human atherosclerosis and in a rat vascular injury model
20. Evidence for apoptosis in advanced human atheroma: Colocalization with interleukin-1β converting enzyme
21. Apoptosis in human atherosclerosis and restenosis
22. Human monocyte/macrophages induce human vascular smooth muscle cell apoptosis in culture
23. Cell surface trafficking of Fas: A rapid mechanism of p53-mediated apoptosis
24. Thrombin generation by apoptotic vascular smooth muscle cells
25. Apoptotic vascular endothelial cells become procoagulant
26. Elevated plasma levels of shed membrane microparticles in patients with acute coronary syndromes
27. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques - A role for apoptosis in plaque thrombogenicity
28. Plaque fissures in human atherosclerotic plaques
29. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology
30. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques
31. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture
32. The sequence of cell and matrix changes in atherosclerotic lesions of coronary arteries in the first forty years of life
33. Characteristics of the plaque under a coronary thrombus
34. Attenuation of media of coronary arteries in advanced atherosclerosis
35. Increased expression of matrix metalloproteinases and matrixdegrading activity in vulnerable regions of human atherosclerotic plaques
36. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases
37. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion
38. Microscopic localization of active proteases by in-situ zymograph - Detection of matrix metalloproteinase activity in vascular tissue
39. TNF-alpha and IL-1beta selectively induce expression of 92-kDa gelatinase by human macrophages
40. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: A role for CD40 signaling in plaque rupture?
41. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: Induction of collagenase, stromelysin, and tissue factor
42. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrixdegrading metalloproteinases and implications for plaque rupture
43. Mechanisms of progression in native coronary artery disease: Role of healed plaque disruption
44. Randomised trial of cholesterol lowering in 4444 pateints with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
45. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
46. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
47. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
48. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
49. Effect of simvastatin on coronary atheroma: The Multicentre Anti-Atheroma Study (MAAS)
50. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events
51. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels
52. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, matrix metalloproteinases and cell death in human carotid plaques favoring lesion stability
53. Changes in the connective tissue proteins, glycosaminoglycans and calcium in the arteries of the cynomolgus monkey during atherosclerotic induction and regression
54. Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits
55. Lipid lowering promotes accumulation of mature smooth muscle cells expressing smooth muscle myosin heavy chain isoforms in rabbit atheroma
56. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: A potential mechanism of lesion stabilization
57. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys
58. Probucol inhibits not only the progression of atherosclerotic disease, but causes a different composition of atherosclerotic lesions in WHHL-rabbits
59. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
60. Long-term effects of pravastatin on plasma concentration of C-reactive protein
61. Inhibition of proinflammatory cytokine production by pravastatin
62. The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro
63. Influence on HMG-COA reductase inhibitors on plaque-forming cell (PFC) response in mice
64. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages
65. Direct inhibitory effects of simvastatin on matrix accumulation in cultured murine mesangial cells
66. HMG-CoA reductase inhibitors reduce acetyl LDL endocytosis in mouse peritoneal macrophages
67. HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein